Citizens Financial Group Inc. RI Makes New $620,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Citizens Financial Group Inc. RI purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, Holdings Channel reports. The firm purchased 6,980 shares of the medical equipment provider’s stock, valued at approximately $620,000.

Other institutional investors also recently modified their holdings of the company. Tacita Capital Inc bought a new stake in Zimmer Biomet in the 2nd quarter worth about $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet in the 2nd quarter worth about $29,000. Elevation Wealth Partners LLC raised its position in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new position in Zimmer Biomet during the 1st quarter valued at about $44,000. Finally, Parvin Asset Management LLC bought a new position in Zimmer Biomet during the 2nd quarter valued at about $47,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent analyst reports. Argus reaffirmed a “buy” rating and set a $125.00 price target on shares of Zimmer Biomet in a report on Thursday, October 22nd. Royal Bank Of Canada boosted their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. UBS Group restated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $104.47.

Zimmer Biomet Trading Up 1.0%

Zimmer Biomet stock opened at $97.39 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $103.70. The company has a market cap of $18.58 billion, a P/E ratio of 23.70, a P/E/G ratio of 2.32 and a beta of 0.49. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $94.95 and a two-hundred day simple moving average of $91.69.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Chad Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.